Levobupivacaine Fresenius Kabi

Levobupivacaine, the active ingredient in Levobupivacaine Fresenius Kabi, is a local anesthetic presented as a sterile solution for epidural, infiltration, intrathecal, and peripheral nerve use. It provides regional anesthesia for surgical procedures, labor, and postoperative pain management in adult patients.

GNH USA supplies Levobupivacaine Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and offers global logistics support for healthcare institutions.

Levobupivacaine is employed in the management of pain through regional anesthetic techniques.

- Surgical anesthesia: provides dense sensory block for operative procedures. - Labor analgesia: offers effective pain relief during childbirth while preserving motor function. - Postoperative pain management: reduces pain intensity and opioid requirement after surgery.

Levobupivacaine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Hypotension: reduced blood pressure due to vasodilation. - Bradycardia: slowed heart rate. - Dizziness: sensation of light‑headedness. - Nausea: feeling of sickness. - Metallic taste: transient taste disturbance. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Seizures: convulsive activity from systemic toxicity. - Cardiac arrest: loss of heart function. - Respiratory depression: inadequate breathing. - Allergic reaction: rash, urticaria, or anaphylaxis. - Prolonged motor block: extended loss of muscle function. - Systemic toxicity: central nervous system and cardiovascular effects.

When using Levobupivacaine, clinicians should observe several safety measures to minimize risk.

- Patient assessment: evaluate cardiovascular and hepatic status before administration. - Dose adjustment in hepatic impairment: reduce dose or increase monitoring. - Avoid intravascular injection: aspirate before injection and use incremental dosing. - Monitor cardiac function: observe ECG and blood pressure during and after administration. - Use with caution in the elderly: consider reduced dose due to increased sensitivity. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levobupivacaine can interact with other agents, influencing its safety profile.

Major Interactions (Avoid): - Concurrent use of other local anesthetics: increases risk of systemic toxicity. - Class I antiarrhythmic drugs (e.g., quinidine): additive cardiac conduction effects. - High‑dose epinephrine: may exacerbate cardiovascular instability. - CYP3A4 inhibitors (e.g., ketoconazole): raise plasma concentrations of Levobupivacaine. - Lithium therapy: potentiates neurotoxic effects.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may enhance hypotensive effect. - Beta‑adrenergic blockers: can augment bradycardia. - General anesthetics (e.g., propofol): additive CNS depression. - Anticonvulsants (e.g., carbamazepine): may alter seizure threshold. - Diuretics: affect plasma protein binding.